Lotus Pharmaceutical Submits NDA to South Korea’s MFDS for Presbyopia Treatment VIZZ 1.44%

Lotus Pharmaceutical has submitted a New Drug Application (NDA) to South Korea’s Ministry of Food and Drug Safety (MFDS) for its product VIZZ 1.44%. The company seeks regulatory approval for the use of this treatment in addressing presbyopia, a common age-related condition that affects near vision in adults.

The submission marks a step toward introducing VIZZ 1.44% as a potential therapeutic option for individuals experiencing presbyopia in South Korea. Presbyopia typically develops with aging, causing difficulty in focusing on close objects. Lotus Pharmaceutical aims to provide an alternative solution through this product, pending approval from the MFDS. Further details regarding the timeline or expected decision from the regulatory body have not been disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

Related posts:

Study Identifies Astrocyte Subset That Suppresses Immune Response in Glioblastoma FDA Expands Approval of Celltrion’s Biosimilar Avtozma to Include Cytokine Release Syndrome Treatment Chromatin Remodeling Linked to Oncogene Suppression in Prostate Cancer Cells Study Links Reduced IGF1 Levels to Impaired Placental Function in Preeclampsia

Author

GOAI